Gregory D Krol

843 total citations
36 papers, 571 citations indexed

About

Gregory D Krol is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Epidemiology. According to data from OpenAlex, Gregory D Krol has authored 36 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cardiology and Cardiovascular Medicine, 19 papers in Internal Medicine and 5 papers in Epidemiology. Recurrent topics in Gregory D Krol's work include Atrial Fibrillation Management and Outcomes (28 papers), Venous Thromboembolism Diagnosis and Management (19 papers) and Antiplatelet Therapy and Cardiovascular Diseases (9 papers). Gregory D Krol is often cited by papers focused on Atrial Fibrillation Management and Outcomes (28 papers), Venous Thromboembolism Diagnosis and Management (19 papers) and Antiplatelet Therapy and Cardiovascular Diseases (9 papers). Gregory D Krol collaborates with scholars based in United States and Brazil. Gregory D Krol's co-authors include Gordon Sze, Scott Kaatz, M. D. F. Deck, James B. Froehlich, Brian Haymart, Geoffrey D. Barnes, Eva Kline‐Rogers, J Kozłowski, Russell Walker and G Sze and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and Radiology.

In The Last Decade

Gregory D Krol

34 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregory D Krol United States 13 231 139 111 109 83 36 571
Arzu Kalaycı Türkiye 14 415 1.8× 107 0.8× 39 0.4× 71 0.7× 132 1.6× 73 684
Kerstin Hogg United Kingdom 13 283 1.2× 382 2.7× 30 0.3× 39 0.4× 80 1.0× 41 588
Maria Bertilsson Sweden 15 354 1.5× 75 0.5× 22 0.2× 60 0.6× 98 1.2× 28 743
Shijun Xia China 12 382 1.7× 43 0.3× 12 0.1× 26 0.2× 84 1.0× 46 553
N. Paleiron France 15 109 0.5× 123 0.9× 80 0.7× 228 2.1× 79 1.0× 46 632
Nicholas Collins Australia 16 499 2.2× 39 0.3× 27 0.2× 498 4.6× 185 2.2× 104 942
Nicholas Sicignano United States 14 240 1.0× 147 1.1× 7 0.1× 79 0.7× 43 0.5× 37 727
Marion Pépin France 10 124 0.5× 40 0.3× 12 0.1× 35 0.3× 92 1.1× 35 418
Juan M. Ruiz-Nodar Spain 16 923 4.0× 143 1.0× 58 0.5× 150 1.4× 50 0.6× 93 1.3k
Hui Yin Lim Australia 12 107 0.5× 144 1.0× 22 0.2× 34 0.3× 47 0.6× 56 399

Countries citing papers authored by Gregory D Krol

Since Specialization
Citations

This map shows the geographic impact of Gregory D Krol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory D Krol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory D Krol more than expected).

Fields of papers citing papers by Gregory D Krol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory D Krol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory D Krol. The network helps show where Gregory D Krol may publish in the future.

Co-authorship network of co-authors of Gregory D Krol

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory D Krol. A scholar is included among the top collaborators of Gregory D Krol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory D Krol. Gregory D Krol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Giuliano, Christopher, Brian Haymart, Scott Kaatz, et al.. (2025). Outcomes of Oral Anticoagulation with Concomitant NSAID Use: A Registry Based Cohort Study. The American Journal of Medicine. 138(12). 1671–1679.e5.
2.
Schaefer, Jordan K., Scott Kaatz, Gregory D Krol, et al.. (2025). A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism. JACC Advances. 4(5). 101714–101714.
3.
Schaefer, Jordan K., Brian Haymart, Scott Kaatz, et al.. (2024). Outcomes of direct oral anticoagulants with aspirin vs warfarin with aspirin: a registry-based cohort study. Research and Practice in Thrombosis and Haemostasis. 8(4). 102449–102449. 2 indexed citations
4.
Schaefer, Jordan K., Christopher Giuliano, Brian Haymart, et al.. (2024). Treatment Versus Prophylactic Apixaban or Rivaroxaban for Extended Venous Thromboembolic Disease Management. Blood. 144(Supplement 1). 699–699. 1 indexed citations
5.
Schaefer, Jordan K., Christopher Giuliano, Brian Haymart, et al.. (2023). Outcomes of Oral Anticoagulation with Concomitant NSAID Use: A Registry Based Cohort Study. Blood. 142(Supplement 1). 5129–5129. 1 indexed citations
6.
Haymart, Brian, Scott Kaatz, Gregory D Krol, et al.. (2021). Comparison of temporary interruption with continuation of direct oral anticoagulants for low bleeding risk procedures. Thrombosis Research. 203. 27–32. 9 indexed citations
7.
Barnes, Geoffrey D., Yun Li, Xiaokui Gu, et al.. (2020). Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry‐based cohort study. Journal of Thrombosis and Haemostasis. 18(8). 2025–2030. 6 indexed citations
8.
Barnes, Geoffrey D., Scott Kaatz, Elizabeth A. Jackson, et al.. (2017). Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics. Implementation Science. 12(1). 87–87. 18 indexed citations
9.
Schaefer, Jordan K., Suman L. Sood, Brian Haymart, et al.. (2017). Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. Blood Advances. 1(26). 2536–2540. 9 indexed citations
10.
11.
Krol, Gregory D, et al.. (2016). A Rare Case of Intraductal Papillary Mucinous Neoplasm of the Biliary Duct in a Patient with Prostate Adenocarcinoma. Case Reports in Gastroenterology. 10(3). 743–748. 1 indexed citations
12.
Haymart, Brian, Xiaokui Gu, Eva Kline‐Rogers, et al.. (2016). Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. Journal of Thrombosis and Thrombolysis. 43(2). 283–288. 21 indexed citations
13.
Minhas, Anum, Qingmei Jiang, Xiaokui Gu, et al.. (2016). Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. Journal of Thrombosis and Thrombolysis. 42(4). 566–572. 3 indexed citations
14.
15.
Putnam, Andrew J., Xiaokui Gu, Brian Haymart, et al.. (2015). The changing characteristics of atrial fibrillation patients treated with warfarin. Journal of Thrombosis and Thrombolysis. 40(4). 488–493. 4 indexed citations
16.
17.
Barnes, Geoffrey D., Xiaokui Gu, Brian Haymart, et al.. (2014). The Predictive Ability of the CHADS2 and CHA2DS2-VASc Scores for Bleeding Risk in Atrial Fibrillation: The MAQI2 Experience. Thrombosis Research. 134(2). 294–299. 29 indexed citations
18.
Ben‐Menachem, Tamir, et al.. (1996). Balancing service and education: improving internal medicine residencies in the managed care era. The American Journal of Medicine. 100(2). 224–229. 11 indexed citations
19.
Sze, Gordon, Stephen M. Bravo, & Gregory D Krol. (1989). Spinal lesions: quantitative and qualitative temporal evolution of gadopentetate dimeglumine enhancement in MR imaging.. Radiology. 170(3). 849–856. 33 indexed citations
20.
Sze, Gordon, et al.. (1988). Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT.. Radiology. 168(1). 187–194. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arzu Kalaycı Breakdown of academic impact, for papers by Kerstin Hogg Breakdown of academic impact, for papers by Maria Bertilsson Breakdown of academic impact, for papers by Shijun Xia Breakdown of academic impact, for papers by N. Paleiron Breakdown of academic impact, for papers by Nicholas Collins Breakdown of academic impact, for papers by Nicholas Sicignano Breakdown of academic impact, for papers by Marion Pépin Breakdown of academic impact, for papers by Juan M. Ruiz-Nodar Breakdown of academic impact, for papers by Hui Yin Lim
Rankless by CCL
2026